TriSalus Life Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLSI research report →
Range $4 – $12
Price Chart
About the company
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors.
- CEO
- Mary T. Szela
- IPO
- 2021
- Employees
- 102
- HQ
- Westminster, CO, US
Get TickerSpark's AI analysis on TLSI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $143.14M
- P/E
- -4.73
- Fwd P/E
- 29.00
- PEG
- -0.03
- P/S
- 3.09
- P/B
- 199.50
- EV/EBITDA
- -6.87
- Div Yield
- 0.00%
- Gross Margin
- 86.46%
- Op Margin
- -62.95%
- Net Margin
- -56.60%
- ROE
- 759.69%
- ROIC
- -65.15%
Latest fiscal year · YoY change
- Revenue
- $45.15M+53.4%
- Gross Profit
- $38.19M+50.8%
- Op Income
- $-26,946,000
- Net Income
- $-39,227,000-18.0%
- EPS
- $-1.84-47.2%
- OCF Growth
- +55.9%
- FCF Growth
- +54.0%
- 52W High
- $7.95
- 52W Low
- $2.17
- 50D MA
- $3.80
- 200D MA
- $4.22
- Beta
- 0.51
- RSI (14)
- 32
- Avg Volume
- 315.43K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
TriSalus posted 11% revenue growth in Q3, but lowered full-year guidance as new sales territories ramped slower than expected and super-selective Y90 cases outpaced its current product coverage until TriNav Advance cleared.· November 10, 2026
- Q3 revenue was $12.9 million, up 11% year over year and 13% sequentially, with gross margin at 86%.
- Full-year 2026 revenue guidance was cut to $46 million-$48 million, reflecting slower expansion-territory ramp and a faster shift to super-selective Y90 procedures.
- TriNav Advance received FDA clearance in September; management said it should cover the small distal vessel cases TriNav could not previously address.
- CMS final rules were a positive: payment for C8004 rises to about $20,910 from about $11,874, and G0577 national pricing was set at about $13,788 per procedure.
- The company ended the quarter with about $41 million in cash and said that should fully fund its strategic growth plan.
Third-quarter revenue was $12.9 million, up approximately 11% from $11.6 million in the prior-year period and up approximately 13% from $11.4 million in Q2. Gross margin was 86% versus 84% a year ago. Adjusted EBITDA loss was approximately $4.7 million versus $5.4 million in Q3 2025. R&D expense was approximately $3.2 million versus $5.7 million a year ago, sales and marketing was approximately $10.7 million versus $6.8 million, and G&A was approximately $4.9 million versus $6.1 million. The company ended with approximately $41 million in cash. For 2026, management updated revenue guidance to $46 million-$48 million, or approximately 2% to 6% growth over full-year 2025, and said it expects a sequential step-up in Q4; no formal 2027 guidance was given, only that more specifics would come on the fourth-quarter call.
Mary Szela framed the quarter as an important growth and portfolio-expansion period, emphasizing that TriSalus is still early in capturing an estimated $2.5 billion U.S. addressable market. She said the company is building a broader evidence base around TriNav, advancing multiple studies across liver indications, and expanding beyond the liver with a disciplined stepwise approach. Her tone was constructive but candid: she acknowledged the slower-than-expected ramp in expansion territories and the faster shift toward super-selective Y90, while stressing that TriNav Advance, reimbursement improvements, and a growing funnel should support acceleration into 2027.
David Patience highlighted that revenue growth was supported by TriNav demand, with gross margin improving to 86% from 84% due to lower average unit cost and manufacturing improvements. He pointed to operating discipline as R&D fell to $3.2 million from $5.7 million, G&A to $4.9 million from $6.1 million, and adjusted EBITDA loss improved to $4.7 million from $5.4 million, while sales and marketing rose to $10.7 million due to the expanded commercial organization. He said the company had about $41 million in cash, which he believes fully funds the strategic growth plan, and reiterated that the updated 2026 revenue guide of $46 million-$48 million reflects the field ramp and the super-selective Y90 shift. He also said the company believes it can move toward lower cash burn on a more stable cost base.
Analysts focused on two issues: the slower ramp in newly added geographies and how much of the market is affected by super-selective Y90 usage. Management said the slower geographies are the expansion territories, about 8 of them, and described the issue as a ramping challenge rather than turnover, with virtually none in the sales force. On super-selective Y90, Mary Szela and Dr. Marshall said the company can now fully address that segment with TriNav Advance, and Marshall explained it is mainly used in very small tumors, including tumors 2 centimeters and smaller. Questions also pushed on Q4 guidance and 2027 growth; management said Q4 does not include Advance revenue yet, and that more 2027 detail will come later, though they remain optimistic about meaningful double-digit growth.
The call offered several concrete catalysts: TriNav Advance has FDA clearance and should broaden the company’s reach into small distal vessels, while CMS reimbursement changes improve the economics of both hospital and office-based lab use. Management also said the ordering account base is growing, September was the strongest month of the year for ordering accounts and units, and newer territories are still growing sequentially. The company also has a substantial evidence program underway, which management believes could strengthen adoption and eventually support guideline inclusion.
The main near-term concern is execution: the company missed expectations because new expansion territories ramped more slowly than planned, and management said that cohort is about 1/3 of the field. There is also a market-mix headwind from the move toward super-selective Y90 procedures in small distal vessels, which reduced near-term revenue until TriNav Advance was cleared. Revenue guidance was lowered, and management declined to include any meaningful Advance revenue in the Q4 outlook, which suggests the product’s commercial impact may take time to show up.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.9%
- Shares Outstanding
- 61.70M
- Float Shares
- 38.18M
of shares held by institutions
81 13F filers
Buy/sell ratio 0.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| First Light Asset Management, LLC | 6.55M | ▲ 1.49M |
| Blackrock, Inc. | 2.61M | ▼ 48.07K |
| Vanguard Capital Management LLC | 1.72M | ▼ 8.71K |
| Cerity Partners LLC | 1.61M | ▲ 1.88K |
| Vanguard Group Inc | 1.53M | ▲ 371.13K |
| Geode Capital Management, LLC | 1.12M | ▼ 66.69K |
| Gilder Gagnon Howe & Co LLC | 850.08K | ▼ 38.43K |
| State Street Corp | 668.90K | ▲ 57.93K |
| Kennedy Capital Management LLC | 625.69K | ▲ 149.43K |
| Thompson Siegel & Walmsley LLC | 529.53K | ▼ 7.00K |
| Nantahala Capital Management, LLC | 500.00K | ▼ 500.00K |
| White Pine Capital LLC | 497.19K | ▼ 50.39K |
Held by 91 ETFs
Biggest fund positions in TLSI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Szela Mary T | buy | 34,328 |
| Nov 17, 26 | Szela Mary T | buy | 30,864 |
| Nov 17, 26 | Gordon Gary B. | buy | 10,000 |
| Nov 16, 26 | Marshak Richard | sell | 544 |
| Nov 12, 26 | Wahlstrom Mats | buy | 50,000 |
| Oct 5, 26 | Cox Bryan F. | sell | 296 |
| Oct 5, 26 | Marshak Richard | sell | 325 |
| Oct 5, 26 | Stevens Jennifer | sell | 316 |
| Oct 5, 26 | Szela Mary T | other | 2,693 |
| Jul 1, 26 | Patience David | other | 14,650 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TLSI coverage
Recent articles, reports, and earnings notes.
No research on TLSI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TLSI report →TriSalus Life Sciences to Participate in the 38th Annual Piper Sandler Healthcare Conference on December 1, 2026
businesswire.com · Nov 17
TriSalus Life Sciences Q3 Earnings Call Highlights
marketbeat.com · Nov 10
TriSalus Life Sciences, Inc. (TLSI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
TriSalus Life Sciences Reports Third Quarter 2026 Results
businesswire.com · Nov 10
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
businesswire.com · Oct 29
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
businesswire.com · Oct 20
Reviewing Innovative Eyewear (NASDAQ:LUCY) and TriSalus Life Sciences (NASDAQ:TLSI)
defenseworld.net · Oct 1
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
benzinga.com · Sep 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.